92. GLP‑1 Controversies: What the Data Really Say

Dr. Leonard Pastrana specializes in cellular optimization medicine and has multiple certifications in peptide therapy from the American Academy of Anti-aging and Seeds Scientific Research and Performance. Dr. Pastrana is a faculty member and one of only six certified clinical instructors from Seeds Scientific research and performance. He is currently the only Pharmacist to have this honor. Dr. Pastrana is also the head supplement formulator for multiple companies, including nuBioAge.

We’re alongside Dr. Pastrana in this episode, welcoming him back to the podcast to address a controversial claim we recently heard about GLP-1 medications causing blindness. Dr. Pastrana debunks myths surrounding GLP-1s, giving all the fact-based details on semaglutide's effects on vision. Boldly challenging the misconceptions surrounding GLP-1 usage, we explore its potential anabolic benefits rather than the feared muscle loss. We also discuss the benefits of peptide combinations like BPC-157 and thymosin beta-4, while also taking on concerns about GLP-1s and cancer risk.

Topics discussed in this episode include:

• Myths surrounding GLP-1s, like semaglutide's impact on vision.
• Why nutritional support is essential for GLP-1 medications to enhance muscle growth.
• How Dr. Pastrana emphasizes scrutinizing research to avoid misconceptions in medical studies.
• Why specific peptide combinations can be beneficial for longevity.
• How GLP-1s positively impact metabolic health and reduce obesity-related cancer risks.
• Why informed medical practice is crucial when interpreting study results on GLP-1s.
• How a case study illustrates GLP-1 GIP's transformative effects on a 72-year-old patient's quality of life.
• How Dr. Pastrana’s longevity certification program offers tools for expanding medical knowledge.
• Why addressing GLP-1 myths about thyroid cancer is important for all practitioners.
• How GLP-1s contribute to reducing obesity-related cancer risks through weight loss.
• Why thorough patient history is vital for identifying GLP-1 contraindications.

CALM 2026: https://nubioage.com/calm 

Longevity Certification course: https://nubioage.com/longevity-certification

Dr. Leonard Pastrana on Instagram: https://www.instagram.com/leonardpastrana 

NuBioAge on Instagram: https://www.instagram.com/nubioagewellnessnetwork 

Follow our Instagram https://www.instagram.com/lexiyoonp or visit us at https://www.yoodirecthealth.com